pharma · Acne Vulgaris
Cutia Therapeutics (Shanghai)
Cutia Therapeutics (Shanghai) Co., Ltd
Cutia Therapeutics (Shanghai) is a pharma organization headquartered in CN. Primary therapeutic focus areas include Acne Vulgaris. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 1
- Patents
- 0
FMX101
Phase 3 · small molecule · Acne Vulgaris
FMX101 for Acne Vulgaris is a Phase 3 program (small_molecule) at Cutia Therapeutics (Shanghai) Co., Ltd with 1 ClinicalTrials.gov record(s).
Internal code CU-10201-301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Cutia Therapeutics (Shanghai) Co., Ltd
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Acne Vulgaris
- Status
- completed
- Trials
- 1